Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. Issue 6 (July 2019)
- Record Type:
- Journal Article
- Title:
- Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. Issue 6 (July 2019)
- Main Title:
- Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases
- Authors:
- Liefferinckx, Claire
Verstockt, Bram
Gils, Ann
Tops, Sophie
Van Moerkercke, Wouter
Vermeire, Severine
Franchimont, Denis - Abstract:
- Background: Very little is known about the impact of the wash-out period on the pharmacokinetics of a second-line biologic. Objective: The objective of this article is to explore the impact of two different wash-out periods on the pharmacokinetics of vedolizumab and infliximab. Methods: Patients switching from infliximab to vedolizumab were retrospectively identified. The population was divided into two groups according to wash-out period: <6 weeks or >6 weeks. Vedolizumab and infliximab trough levels (TLs) were determined and correlated with clinical and biological outcomes. Results: A total of 71 inflammatory bowel disease patients were included. At week 6, in patients previously treated with infliximab, median vedolizumab TLs were 21.9 µg/ml and 24.9 µg/ml for the <6 weeks and >6 weeks wash-out period, respectively ( p = 0.31), whereas median residual infliximab TLs were 0.5 µg/ml and 0 µg/ml ( p = 0.034). The rate of treatment discontinuation was similar ( p = 0.64), and the infectious events were six and two for the <6 weeks and >6 weeks wash-out period, respectively ( p = 0.12) by week 30. Conclusions: This study suggests clinicians may not need to be concerned about the impact of wash-out period on the pharmacokinetics of the second-line biologic when switching infliximab to vedolizumab. More data are required on the impact of wash-out period on safety.
- Is Part Of:
- United European Gastroenterology journal. Volume 7:Issue 6(2019)
- Journal:
- United European Gastroenterology journal
- Issue:
- Volume 7:Issue 6(2019)
- Issue Display:
- Volume 7, Issue 6 (2019)
- Year:
- 2019
- Volume:
- 7
- Issue:
- 6
- Issue Sort Value:
- 2019-0007-0006-0000
- Page Start:
- 750
- Page End:
- 758
- Publication Date:
- 2019-07
- Subjects:
- Induction -- inflammatory bowel disease -- infliximab -- pharmacokinetics -- trough level -- vedolizumab -- wash-out
Gastroenterology -- Periodicals
Periodicals
616.33005 - Journal URLs:
- https://onlinelibrary.wiley.com/loi/20506414 ↗
http://www.uk.sagepub.com ↗
http://ueg.sagepub.com/ ↗ - DOI:
- 10.1177/2050640619841538 ↗
- Languages:
- English
- ISSNs:
- 2050-6406
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11541.xml